$クエスト・ダイアグノスティクス (DGX.US)$PathAI + Invigorate + stable finance + qualified management team + decent PE. Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
The Covid-19 pandemic isn’t over but the U.S. is already entering a new vaccine boom. But the delayed vaccine rollout continues to raise questions. CNN reports that the U.S. delayed a large-scale vaccine order out of fear of the shots expiring before being administered. Federal agencies are exploring new ways to provide vaccines more efficiently, but the supply shortage poses challenges. For the U.S. government,...
クエスト・ダイアグノスティクスに関するコメント
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
He became a millionaire many times over on a modest federal salary from trading.
Take a look:
Thomas Carper bought 30k in $ProShares Short QQQ (PSQ.US)$ , an ultrashort $インベスコQQQ 信託シリーズ1 (QQQ.US)$ index, on July 13 2023.
He hedged/shorted in the past with great results with $Advisorshares Trust Ranger Equity Bear Etf (HDGE.US)$ , ...
In reaction to earnings/guidance:
• $スーパー・マイクロ・コンピューター (SMCI.US)$ +18%, $ノキア (NOK.US)$ +7.7%, $ダナハー (DHR.US)$ +6.3%, $アールエルアイ (RLI.US)$ +5%, $シーエスエックス (CSX.US)$ +4.3%, $ラスベガス・サンズ (LVS.US)$ +4.2%, $アルコア (AA.US)$ +3.4%(also authorizes new $500 mln share repurchase program)
• $スチール・ダイナミクス (STLD.US)$ +2.8%, $ハーク・ホールディングス (HRI.US)$ +2.6%, $テスラ (TSLA.US)$ +2.5%, $フィリップ・モリス・インターナショナル (PM.US)$ +2.5%, $エフエヌビー (FNB.US)$ ...
• $ツイッター (TWTR.US)$ +20.5% (Elon Musk discloses 9.2% passive stake)
• $キャムテック (CAMT.US)$ +9.6%, $ぺリオン・ネットワーク (PERI.US)$ +6.6% (In reaction to earnings/guidance)
• $ニウ・テクノロジーズ (NIU.US)$ +5% (reports QI sales volume increased 9.4% yr/yr)
• $アイロン・スパーク・I (ISAA.US)$ +3.4% (Hypebeast plans to list on NASDAQ through Merger with Iron Spark I)
• $ガトス・シルバー (GATO.US)$ +2.3% (Provides Bi-Weekly Status Report)
• $ヴァーヴ・セラピューティクス (VERV.US)$ +1.8% (re...
• $DCP ミッドストリーム・パートナーズ (DCP.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $42 (from $36)
• $レスリーズ (LESL.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $27 (from $26)
• $ロジテック・インターナショナル (LOGI.US)$ : Goldman Sachs Upgrades to Buy from Neutral
• $ニオ (NIO.US)$ : UBS Upgrades to Buy from Neutral - PT $32 (from $46)
• $オーリーズ・バーゲン・アウトレット・ホールディングス (OLLI.US)$ : Wells Fargo Upgrades to Overweight from EqualWeight - PT $65 (from $45)
• $オリック・ファーマシューティカルズ (ORIC.US)$ : Citigro...
まだコメントはありません